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discharge, registry patients experienced a 42% reduction in NYHA
class III-IV symptoms. In-hospital mortality was numerically lower
among registry patients (2.7% vs. 4.6, p¼0.27). Need for blood
transfusions were similar in registry and clinical trial patients (9.1%
vs. 12.5%, p¼0.21). There were no differences in the occurrence of
other complications such as acute kidney failure, vascular injury or
ventricular arrhythmias.
CONCLUSIONS USpella provides a real world and contemporary
estimation of the type of procedures and outcomes of high-risk pa-
tients undergoing PCI supported by Impella 2.5. Despite the higher
risk of registry patients, clinical outcomes appeared to be favorable
and consistent compared with the randomized trial.
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BACKGROUND We sought to describe contemporary guidewire utili-
zation for antegrade wire escalation during chronic total occlusion
(CTO) percutaneous coronary intervention (PCI).
METHODS We examined guidewire and microcatheter utilization
during antegrade wire escalation attempts among 1097 CTO PCIs
performed at 13 experienced US centers between May 2012 and April
2015 using the hybrid approach.
RESULTS Mean age was 65  9.8 years, 83.2% of the patients were
men and 33.3% had prior coronary bypass graft surgery. Technical and
procedural success was 90.6% and 87.6%, respectively. Antegrade
wire escalation was used in 780 procedures (71.1%), and was the ﬁnal
successful crossing strategy in 463 procedures (59.3%). A total of 1630
guidewires (2.4  1.4 per procedure) were used for antegrade wire
escalation. The most frequently used guidewires were the Pilot 200
(Abbott Vascular, 24.7%), Fielder XT (Asahi Intecc, 19.7%), and the
Conﬁanza Pro 12 (Asahi Intecc, 12.6%) (Figure 1). The same guidewires
were the ones that most commonly led to successful CTO crossing:
Pilot 200 (35.2% of successful antegrade wire crossings), Fielder XT
(20%) and Conﬁanza Pro 12 (10.7%). A microcatheter or over-the-wire
balloon was used in 73.8% of antegrade wire escalation cases, as fol-
lows: Corsair (Asahi-Intecc, 42.8%), Finecross (Terumo, 18.6%), over-
the-wire balloon (14.2%), CrossBoss (Boston Scientiﬁc, 12.7%), and
Venture (St Jude Medical, 3.3%).CONCLUSIONS Our contemporary, multicenter CTO PCI registry demon-
strates remarkable consistency in guidewire selection for antegrade wire
escalation, with polymer-jacketed guidewires being used in most cases
including most successfully crossed cases. Upfront use of the Pilot 200
guidewire might offer the best chance for successful guidewire crossing.
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BACKGROUND The prevalence of native coronary CTO following cor-
onary artery bypass grafts (CABG) is high. At 10 years following CABG,
half patients will have at least one saphenous vein graft (SVG) occluded
and/or many SVGs will be diseased. Long-term outcome post SVG PCI is
poor, with high occlusion rate. If symptomatic, these patients may be
considered for a native coronary CTO PCI rather than SVG PCI. We
examined the feasibility and outcomes of CTO PCI using a patent or
occluded SVG as a retrograde conduit to the native CTO vessel.
METHODS Our preferred wire to cross an occluded SVG is Pilot 200
(Abbott Vascular, US) followed by amicrocatheter (MC) (usually Corsair,
Asahi Intecc, Japan), whereas standard workhorse wire can be used in
patent but diseased SVGs or arterial graft. MC tip injection is performed
to assess if the wire tracked the vein structure in case of an occluded
SVG. Clips and other surgical landmarks are used to track the occluded
graft with the wire. Once the MC is at the distal CTO cap, standard
techniques to open CTO are employed. We assessed the proportion of
patients treated with such technique from SVGs. We speciﬁcally
reviewed the J-CTO score, the prevalence of occluded vs. patent graft,
the type of graft crossed (SVG or arterial graft), technical success and
management of the graft after successful PCI of the native CTO.
RESULTS From 03.2009 to 04.2015 431 CTO PCI cases were performed
by a single operator (SR) or a teamof 2 operators (SR andCMN). Of these,
156 (36.2%) were done in post-CABG patients. In the post-CABG cohort,
an antegrade approach was used in 68 (43.6%) and a retrograde in 88
(56.4%) of cases. In the retrograde approach, septal collateral channels
(CCs) were used in 26 (29.5%), epicardial in 34 (38.6%) and SVGs in 28
(31.8%) of cases. Technical success of CTO revascularization in post-
CABG patients (J-CTO score 2.510.1) was 91%. In the sub-group treated
from an SVG,mean J-CTO score was 3.040.19. The CTO locationwas in
the right coronary artery in 43%, left circumﬂex in 43%, left anterior
descending in 7% and in the left main in 7%. When using an SVG, suc-
cess was achieved in 27 cases (96.4%). A total of 15 SVGs (53.6%) were
occluded before the retrograde attempt, and the oldest occlusion was
4-years old. Most common native coronary CTO recanalization
